Alembic Pharmaceuticals has reported results for first quarter ended June 30, 2016.
The company has reported 53.22% rise in its net profit after tax at Rs 119.74 crore for the quarter ended June 30, 2016 as compared to Rs 78.15 crore for the same quarter in the previous year. The company’s total income increased by 20.01% to Rs 688.98 crore for the quarter under review from Rs 574.10 crore for the corresponding quarter of the previous year.
On the consolidated basis, the company has reported 44.64% rise in its net profit after taxes and share of profit of associates at Rs 103.75 crore for the quarter ended June 30, 2016 as compared to Rs 71.73 crore for the same quarter in the previous year. Total Income of the company increased by 25.04% to Rs 728.42 crore for the quarter under review from Rs 582.57 crore for the same quarter ended June 30, 2015.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: